Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials

por Hindiyeh, Nada A., Kellerman, Donald J., Schmidt, Peter C.
Publicado 2019

Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult‐to‐Treat Migraine Headaches

por Tepper, Stewart J., Dodick, David W., Schmidt, Peter C., Kellerman, Donald J.
Publicado 2019

Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine

por Noveck, Robert J, Douglas, Pamela S, Chow, Shein-Chung, Mangum, Barry, Kori, Shashidhar, Kellerman, Donald J
Publicado 2013

Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post‐Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial

por Dodick, David W., Tepper, Stewart J., Friedman, Deborah I., Gelfand, Amy A., Kellerman, Donald J., Schmidt, Peter C.
Publicado 2018

Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine

por Nahas, Stephanie J., Hindiyeh, Nada, Friedman, Deborah I., Elbuluk, Nada, Kellerman, Donald J., Foreman, Pamela K., Schmidt, Peter
Publicado 2021

Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine

por Spierings, Egilius LH, Brandes, Jan Lewis, Kudrow, David B, Weintraub, James, Schmidt, Peter C, Kellerman, Donald J, Tepper, Stewart J
Publicado 2017